GO:0006382 adenosine to inosine editing: RNA Modification Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006382 adenosine to inosine editing is the enzymatic conversion of adenosine to inosine in RNA by deamination, a process that expands the informational content of the transcriptome.
• The reaction is catalyzed by ADAR enzymes (ADAR, ADARB1, ADARB2), which bind double-stranded RNA and deaminate adenosine to inosine, which is then read as guanosine by the translational machinery.
• A-to-I editing is essential for neurological development and function, and its dysregulation is linked to neurological disorders and cancer.
• Editing can alter protein-coding sequences, splice sites, microRNA binding sites, and RNA stability, thereby affecting diverse cellular processes.
• A-to-I editing is dynamically regulated and can be studied using RNA-seq, Ribo-seq, and targeted CRISPR-based models.
• EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression, and library screening services to dissect the function of A-to-I editing in health and disease.
Description
Adenosine to inosine editing (GO:0006382) is a post-transcriptional RNA modification in which adenosine residues are hydrolytically deaminated to inosine within RNA molecules. This process is catalyzed by the adenosine deaminase acting on RNA (ADAR) family of enzymes and represents a major source of transcriptome diversification. Because inosine is recognized as guanosine by the cellular machinery, A-to-I editing can recode genetic information, alter RNA secondary structure, and modulate interactions with proteins and non-coding RNAs. The importance of A-to-I editing is underscored by its essential roles in neurological development and disease, as well as its emerging involvement in cancer and immune regulation. Researchers study this process to understand how RNA editing contributes to normal physiology and how its dysregulation leads to pathology, making it a compelling target for therapeutic intervention.
adenosine to inosine editing At A Glance
| GO ID | GO:0006382 |
|---|---|
| GO term | adenosine to inosine editing |
| Ontology | biological_process |
| Synonym | None |
| Definition | The conversion of an adenosine residue to inosine in an RNA molecule by deamination. |
| Major function | Post-transcriptional RNA modification that recodes genetic information and diversifies the transcriptome. |
| Key enzymes | ADAR, ADARB1, ADARB2 |
| Substrate | Adenosine within double-stranded RNA |
| Product | Inosine, which base-pairs as guanosine |
What Is GO:0006382?
According to the Gene Ontology, adenosine to inosine editing (GO:0006382) is defined as the conversion of an adenosine residue to inosine in an RNA molecule by deamination. This enzymatic modification occurs on adenosine within double-stranded RNA regions and is catalyzed by ADAR enzymes. The resulting inosine is subsequently interpreted as guanosine during translation and other RNA transactions, effectively altering the RNA sequence and its functional properties.
Why Is adenosine to inosine editing Important in Cell Biology?
Adenosine to inosine editing is critically important because it enables organisms to expand the coding capacity of their genomes and fine-tune gene expression without altering DNA. This modification is essential for normal development, particularly in the nervous system, where it regulates synaptic transmission and neuronal excitability. Dysregulated A-to-I editing has been implicated in a wide range of human diseases, including neurological disorders, autoimmune conditions, and multiple cancer types. Understanding the mechanisms and consequences of A-to-I editing is therefore fundamental to both basic biology and translational medicine.
• A-to-I editing diversifies the proteome by recoding codons, affecting protein function.
• It is essential for normal neurological development and function.
• Dysregulation of editing is associated with neurodegenerative and psychiatric disorders.
• Altered A-to-I editing patterns are observed in many cancers and can drive oncogenesis.
• Editing can modulate immune responses by altering viral RNA and endogenous dsRNA.
• It affects RNA stability, splicing, and microRNA targeting.
• A-to-I editing is involved in drug metabolism by modifying transcripts of drug-metabolizing enzymes.
• It serves as a potential biomarker and therapeutic target in cancer.
• Editing enzymes are regulated by inflammation and stress responses.
• CRISPR-based models enable precise dissection of editing events and their functional consequences.
What Happens During adenosine to inosine editing?
Recognition of Double-Stranded RNA
In simple terms: The editing enzyme first binds to double-stranded RNA regions in the target transcript.
ADAR enzymes contain double-stranded RNA-binding domains that recognize and bind to duplex RNA structures formed by intramolecular base-pairing within the target RNA. This binding is a prerequisite for catalytic activity and determines substrate specificity. The structural features of the RNA duplex, including mismatches and bulges, influence editing efficiency and site selectivity.
Deamination of Adenosine to Inosine
In simple terms: The enzyme chemically removes an amino group from adenosine, converting it to inosine.
The catalytic domain of ADAR enzymes performs hydrolytic deamination of adenosine, removing an amino group and converting it to inosine. This reaction occurs within the active site and requires the presence of the target adenosine flipped out of the RNA duplex. The resulting inosine is structurally similar to guanosine and is subsequently read as guanosine by the translational machinery.
Functional Consequences of Editing
In simple terms: The change from adenosine to inosine can alter the meaning of the RNA message.
Depending on the location of the editing event, A-to-I editing can lead to amino acid substitutions in proteins (recoding), creation or destruction of splice sites, changes in RNA secondary structure, and altered interactions with microRNAs or RNA-binding proteins. These changes can affect protein function, gene expression, and cellular signaling pathways.
Regulation of Editing Activity
In simple terms: The amount and activity of editing enzymes are controlled by cellular signals.
ADAR expression and activity are regulated at multiple levels, including transcription, alternative splicing, and post-translational modifications. Inflammatory signals can prime tissues for recovery by activating A-to-I editing, as shown in murine kidney models. Additionally, editing can be influenced by the availability of double-stranded RNA substrates and interacting proteins.
Key Genes Involved in GO:0006382 adenosine to inosine editing
The following genes encode the enzymes and regulatory factors that mediate adenosine to inosine editing, and they are frequently studied in functional genomics research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADAR | Catalyzes adenosine to inosine deamination in double-stranded RNA | Central enzyme for A-to-I editing; mutations linked to neurological disorders |
| ADARB1 | Catalyzes adenosine to inosine deamination; primarily edits neuronal transcripts | Implicated in synaptic function and neurological disease |
| ADARB2 | Catalyzes adenosine to inosine deamination; may have regulatory roles | Less studied; potential roles in development and disease |
| AZIN1 | Target of A-to-I editing; editing alters protein function | Editing of AZIN1 is linked to cancer progression and kidney recovery |
| GLI1 | Target of A-to-I editing; editing affects Hedgehog signaling | Editing of GLI1 can promote tumorigenesis |
| GRIA2 | Target of A-to-I editing; editing controls calcium permeability of AMPA receptors | Critical for neuronal excitability; editing defects linked to neurological disorders |
| HTR2C | Target of A-to-I editing; editing affects serotonin receptor signaling | Editing alterations associated with psychiatric disorders |
| GABRA3 | Target of A-to-I editing; editing modulates GABA receptor function | Editing changes affect inhibitory neurotransmission |
| KCNA1 | Target of A-to-I editing; editing affects potassium channel function | Editing may influence neuronal excitability |
| FLNA | Target of A-to-I editing; editing alters cytoskeletal protein function | Editing of FLNA linked to cancer and developmental disorders |
| CYP2C8 | Drug-metabolizing enzyme; A-to-I editing modulates its expression | Editing affects drug metabolism and response |
| CYP2C9 | Drug-metabolizing enzyme; A-to-I editing modulates its expression | Editing affects drug metabolism and response |
| CYP2C19 | Drug-metabolizing enzyme; A-to-I editing modulates its expression | Editing affects drug metabolism and response |
| CYP3A4 | Drug-metabolizing enzyme; A-to-I editing modulates its expression | Editing affects drug metabolism and response |
| CYP2D6 | Drug-metabolizing enzyme; A-to-I editing modulates its expression | Editing affects drug metabolism and response |
| CYP1A2 | Drug-metabolizing enzyme; A-to-I editing modulates its expression | Editing affects drug metabolism and response |
| CYP2B6 | Drug-metabolizing enzyme; A-to-I editing modulates its expression | Editing affects drug metabolism and response |
| CYP2A6 | Drug-metabolizing enzyme; A-to-I editing modulates its expression | Editing affects drug metabolism and response |
How Is adenosine to inosine editing Regulated?
Adenosine to inosine editing is regulated at multiple levels. The expression of ADAR enzymes is controlled by transcriptional and post-transcriptional mechanisms, including alternative splicing and microRNA-mediated regulation. Inflammatory signaling can activate A-to-I editing; for example, inflammation primes the murine kidney for recovery by activating AZIN1 editing. Additionally, the availability of double-stranded RNA substrates and the presence of interacting proteins can modulate editing efficiency. Dysregulation of these regulatory pathways contributes to disease pathogenesis, including cancer and neurological disorders.
adenosine to inosine editing and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADAR | Aicardi-Goutieres syndrome, neurological disorders | Knockout or point-mutation knock-in in neuronal cell lines or organoids |
| AZIN1 | Cancer progression, kidney injury recovery | Knock-in of edited or unedited AZIN1 in cancer cell lines or kidney epithelial cells |
| GLI1 | Cancer (e.g., basal cell carcinoma, medulloblastoma) | Overexpression of edited GLI1 in cancer cell lines |
| GRIA2 | Neurological disorders, epilepsy | Point-mutation knock-in of edited GRIA2 in neurons |
| HTR2C | Psychiatric disorders | Knock-in of edited HTR2C in neuronal cell lines |
A-to-I Editing in Cancer
Altered A-to-I editing patterns are frequently observed in cancer, where they can contribute to tumor initiation and progression. Editing of specific targets such as AZIN1 and GLI1 can promote oncogenic phenotypes. Furthermore, A-to-I editing can affect the expression of drug-metabolizing enzymes, influencing chemotherapy response. These findings highlight the potential of editing events as biomarkers and therapeutic targets.
A-to-I Editing in Neurological Disorders
A-to-I editing is essential for normal neurological function, and its dysregulation is associated with a range of neurological and psychiatric disorders. Editing of neurotransmitter receptors such as GRIA2 and HTR2C affects synaptic transmission and neuronal excitability. Mutations in ADAR cause Aicardi-Goutieres syndrome, a severe neurodevelopmental disorder. Understanding these links provides insights into disease mechanisms and potential therapeutic strategies.
A-to-I Editing in Kidney Injury and Recovery
Recent studies have shown that inflammation primes the murine kidney for recovery by activating AZIN1 A-to-I editing. This suggests that A-to-I editing plays a role in tissue repair and regeneration, and may be a target for enhancing recovery after kidney injury.
From adenosine to inosine editing-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of ADAR knockout on global A-to-I editing? | ADAR knockout cell lines (e.g., HEK293, HeLa) |
| How does a specific editing site affect protein function? | Point-mutation knock-in of the edited or unedited base in the target gene |
| What are the consequences of expressing a catalytically inactive ADAR? | Knock-in of a catalytically dead ADAR mutant |
| How does overexpression of ADAR affect transcriptome editing? | Overexpression of wild-type or mutant ADAR in cell lines |
| What is the role of AZIN1 editing in kidney recovery? | Knock-in of edited AZIN1 in kidney epithelial cells or mouse models |
| Can CRISPR screening identify regulators of A-to-I editing? | CRISPR library screening in cells expressing an editing reporter |
How to Study the adenosine to inosine editing Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome-wide A-to-I editing events | Detecting and quantifying editing sites |
| Ribo-seq | Ribosome occupancy and translation efficiency | Assessing translational impact of editing |
| Proteomics | Protein expression and modifications | Validating recoding events |
| Site-specific editing assays | Editing efficiency at a specific site | Functional studies of individual editing events |
| CRISPR knockout | Loss of editing enzyme function | Determining requirement for ADAR in editing |
| CRISPR knock-in | Introduction of specific editing mutations | Modeling disease-associated editing changes |
| CRISPR library screening | Identification of regulators of editing | High-throughput discovery of editing modulators |
RNA Sequencing for Editing Detection
RNA-seq is widely used to detect A-to-I editing events transcriptome-wide by identifying A-to-G mismatches relative to the reference genome. This approach enables the quantification of editing levels at specific sites and the discovery of novel editing events. Careful bioinformatic analysis is required to distinguish editing from genomic variants and sequencing errors.
Ribo-seq for Translational Impact
Ribo-seq measures ribosome occupancy and can reveal how A-to-I editing affects translation efficiency and protein synthesis. By combining RNA-seq and Ribo-seq, researchers can determine whether editing events alter the translational landscape.
Proteomics for Functional Consequences
Mass spectrometry-based proteomics can identify protein-level changes resulting from recoding editing events. This is particularly useful for validating the functional impact of specific editing sites on protein sequence and abundance.
Imaging and Reporter Assays
Fluorescent reporters and imaging techniques can visualize editing activity in live cells and tissues. Reporter assays using edited versus unedited sequences can quantify editing efficiency and screen for modulators.
How CRISPR Can Be Used to Study GO:0006382 adenosine to inosine editing
Knockout
CRISPR knockout of ADAR or ADARB1 eliminates A-to-I editing activity, allowing researchers to study the consequences of loss of editing on gene expression, cellular phenotypes, and disease models. Knockout cell lines are valuable for identifying editing-dependent pathways and validating specific editing events.
Point Mutation
Point mutations can be introduced into the catalytic domain of ADAR to create catalytically inactive enzymes, or into specific editing sites to mimic edited or unedited states. These models help dissect the functional significance of individual editing events and enzyme activities.
Knock-in
Knock-in of edited or unedited sequences at endogenous loci enables precise modeling of disease-associated editing changes. For example, knocking in the edited form of AZIN1 can recapitulate its oncogenic effects in cancer cell lines.
Overexpression
Overexpression of wild-type or mutant ADAR enzymes can enhance or alter editing patterns, providing a gain-of-function approach to study editing biology. This is useful for identifying downstream targets and for screening small-molecule modulators of editing.
How EDITGENE Supports adenosine to inosine editing Research
Researchers studying adenosine to inosine editing-related genes often need to determine whether a candidate gene is causally involved in the editing process or its downstream effects. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise functional interrogation of A-to-I editing components and their targets.
Contact EDITGENE today to design your custom CRISPR model for adenosine to inosine editing research.
Frequently Asked Questions About adenosine to inosine editing
What is adenosine to inosine editing?
Adenosine to inosine editing (GO:0006382) is the enzymatic conversion of adenosine to inosine in RNA by deamination, catalyzed by ADAR enzymes.
What genes are involved in adenosine to inosine editing?
The main genes are ADAR, ADARB1, and ADARB2, which encode the enzymes that catalyze the reaction.
How does A-to-I editing affect protein function?
Editing can change codons, leading to amino acid substitutions that alter protein function, as seen in targets like AZIN1 and GLI1.
What diseases are linked to A-to-I editing?
Dysregulated editing is associated with neurological disorders, cancer, and kidney injury, among others.
What methods are used to study A-to-I editing?
Common methods include RNA-seq, Ribo-seq, proteomics, and site-specific editing assays.
Can CRISPR be used to study A-to-I editing?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are powerful tools for dissecting editing mechanisms.
What is the role of ADAR in the nervous system?
ADAR-mediated editing is essential for normal neuronal function, and its dysregulation leads to neurological disorders.
How is A-to-I editing regulated?
Editing is regulated by ADAR expression, inflammatory signals, and RNA substrate availability.
Is A-to-I editing important in cancer?
Yes, altered editing patterns contribute to cancer development and progression, making them potential biomarkers and targets.
What services does EDITGENE offer for editing research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services tailored to A-to-I editing studies.
Conclusion
Adenosine to inosine editing (GO:0006382) is a fundamental RNA modification that expands the coding potential of the genome and plays critical roles in development, physiology, and disease. Its dysregulation is implicated in neurological disorders, cancer, and tissue injury, making it a vibrant area of research. Advances in CRISPR-based models and high-throughput sequencing are accelerating our understanding of this process and opening new avenues for therapeutic intervention.
References
- 1. Yang Y et al.. 2021. Adenosine-to-inosine RNA editing in neurological development and disease.. RNA Biol 18(7):999-1013 PMID: 33393416
- 2. Zinshteyn B et al.. 2009. Adenosine-to-inosine RNA editing.. Wiley Interdiscip Rev Syst Biol Med 1(2):202-209 PMID: 20835992
- 3. Gan WL et al.. 2023. Recent Advances in Adenosine-to-Inosine RNA Editing in Cancer.. Cancer Treat Res 190:143-179 PMID: 38113001
- 4. Heruye SH et al.. 2024. Inflammation primes the murine kidney for recovery by activating AZIN1 adenosine-to-inosine editing.. J Clin Invest 134(17) PMID: 38954486
- 5. Cheng H et al.. 2025. Adenosine-to-inosine RNA editing in cancer: molecular mechanisms and downstream targets.. Protein Cell 16(6):391-417 PMID: 39126156
- 6. Nakano M et al.. 2022. Adenosine-to-Inosine RNA Editing and N (6)-Methyladenosine Modification Modulating Expression of Drug Metabolizing Enzymes.. Drug Metab Dispos 50(5):624-633 PMID: 35152204
- 7. Gatsiou A et al.. 2018. Adenosine-to-Inosine RNA Editing in Health and Disease.. Antioxid Redox Signal 29(9):846-863 PMID: 28762759
- 8. Dominissini D et al.. 2011. Adenosine-to-inosine RNA editing meets cancer.. Carcinogenesis 32(11):1569-77 PMID: 21715563
